The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer-Reference-Cited by-同舟云学术

The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer

Published:2012-07 Issue:1 Volume:104 Page:67-71
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

van Elmpt Wouter,De Ruysscher Dirk,van der Salm Anke,Lakeman Annemarie,van der Stoep Judith,Emans Daisy,Damen Eugène,Öllers Michel,Sonke Jan-Jakob,Belderbos José

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference24 articles.

1. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours;Goldstraw;J Thorac Oncol,2007

2. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer;Auperin;J Clin Oncol,2010

3. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)fluorodeoxyglucose-PET–CT scan;Aerts;Radiother Oncol,2009

4. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?;Abramyuk;Radiother Oncol,2009

5. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study;Aerts;Int J Radiat Oncol Biol Phys,2008

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial;The Lancet Oncology;2024-09

2. Neue radioonkologische Therapiekonzepte beim nicht metastasierten Lungenkarzinom;Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie;2024-08

3. GWO+RuleFit: rule-based explainable machine-learning combined with heuristics to predict mid-treatment FDG PET response to chemoradiation for locally advanced non-small cell lung cancer;Physics in Medicine & Biology;2024-07-23

4. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial;Radiotherapy and Oncology;2024-07

5. Advancements and future directions in positron emission tomography-guided radiotherapy: a narrative review;Chinese Clinical Oncology;2024-04